New combo therapy for HPV throat cancer shows promise in early trial
NCT ID NCT03799445
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 38 times
Summary
This phase 2 study tested a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus radiation therapy in 37 patients with advanced HPV-positive throat cancer. The goal was to see if the treatment was safe and could shrink or eliminate tumors. The study was terminated early, but results help guide future research on using the immune system to fight this cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE I HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.